<DOC>
	<DOCNO>NCT00772590</DOCNO>
	<brief_summary>A research study measure effect CD4 count add current anti-retroviral regimen raltegravir without hyper-immune bovine colostrum .</brief_summary>
	<brief_title>Antiretroviral Therapy Intensification With Raltegravir Addition Hyper-immune Bovine Colostrum HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response</brief_title>
	<detailed_description>The primary objective study measure effect CD4+ T cell outcome measure mean time weight CD4+ T cell count change 24 week two intervention : ( I ) cART intensification raltegravir ( II ) cART combine hyper-immune bovine colostrum HIV-1 infected individual fail achieve CD4+ T cell count great 350 cells/µL despite persistent HIV plasma viraemia 50 copies/mL cART . Eligible patient randomise one four arm . I. Raltegravir + hyper-immune bovine colostrum placebo II . Raltegravir placebo + hyper-immune bovine colostrum III . Raltegravir + hyper-immune bovine colostrum IV . Raltegravir placebo + hyper-immune bovine colostrum placebo</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Documented HIV1 infection Age &gt; 18 year Signed informed consent Receiving combination ART ( cART ) least 12 month stable cART regimen minimum 6 month . A formulation change modification dosage schedule acceptable ( example ritonavir boost lopinavir capsule tablet , abacavir ( ABC ) tenofovir ( TDF ) lamivudine ( 3TC ) emtricitabine ( FTC ) single agent ABC/3TC TDF/FTC fix dose combination ) Two consecutive plasma HIV RNA viral load measurement &lt; 50 ( &lt; 400 copies/mL depend upon low level detection local assay ) 9 month precede screen visit . A single isolated HIV RNA viral load &gt; 50 ( &gt; 400 ) copies/mL exclude patient provide viral load result &gt; 50 ( 400 ) copies/mL therapy follow previous result &lt; 50 ( 400 ) copies/mL , followup result &lt; 50 copies/mL least one week follow &gt; 50 ( 400 ) copies/mL read absence change component ART regimen . CD4+ T cell count &lt; 350 cells/µL throughout 6 month precede screen visit &lt; 50 cells/µL increase last 12 month Receiving cART regimen contain integrase inhibitor Anticipated change cART 24 week follow randomisation Participating study investigational compound device within 30 day sign informed consent Use immune modulate therapy immunosuppressive medication within 60 day prior study entry . Patients use inhaled nasal steroid exclude Pregnant breastfeed woman Cow 's milk allergy Concurrent treatment phenobarbitol , phenytoin rifampicin . A know cause impaired CD4+ T cell gain : example , patient splenomegaly individual whose current cART regimen contain tenofovir didanosine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>antiretroviral therapy intensification</keyword>
	<keyword>suboptimal CD4+ T cell response</keyword>
	<keyword>virological suppression</keyword>
	<keyword>bovine colostrum</keyword>
	<keyword>raltegravir</keyword>
</DOC>